BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38323317)

  • 21. Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.
    Fisher JP; Flutter B; Wesemann F; Frosch J; Rossig C; Gustafsson K; Anderson J
    Oncoimmunology; 2016; 5(1):e1025194. PubMed ID: 26942051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of CD11b
    Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN
    Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring CD8a
    Kristensen LK; Christensen C; Alfsen MZ; Cold S; Nielsen CH; Kjaer A
    Mol Imaging Biol; 2020 Aug; 22(4):1021-1030. PubMed ID: 32086762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
    Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
    Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
    Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
    J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.
    Förster-Waldl E; Riemer AB; Dehof AK; Neumann D; Brämswig K; Boltz-Nitulescu G; Pehamberger H; Zielinski CC; Scheiner O; Pollak A; Lode H; Jensen-Jarolim E
    Mol Immunol; 2005 Feb; 42(3):319-25. PubMed ID: 15589320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
    Heczey A; Xu X; Courtney AN; Tian G; Barragan GA; Guo L; Amador CM; Ghatwai N; Rathi P; Wood MS; Li Y; Zhang C; Demberg T; Di Pierro EJ; Sher AC; Zhang H; Mehta B; Thakkar SG; Grilley B; Wang T; Weiss BD; Montalbano A; Subramaniam M; Xu C; Sachar C; Wells DK; Dotti G; Metelitsa LS
    Nat Med; 2023 Jun; 29(6):1379-1388. PubMed ID: 37188782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
    Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
    PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
    Chan GC; Chan CM
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.
    Sun H; England CG; Hernandez R; Graves SA; Majewski RL; Kamkaew A; Jiang D; Barnhart TE; Yang Y; Cai W
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2169-2179. PubMed ID: 27342417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.
    Li L; Lin X; Wang L; Ma X; Zeng Z; Liu F; Jia B; Zhu H; Wu A; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3735-3749. PubMed ID: 37382662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice.
    Aghevlian S; Wu B; Raie MN; Tumbale SK; Kare AJ; Seo JW; Ferrara KW
    Nucl Med Biol; 2021; 98-99():8-17. PubMed ID: 33962357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
    Seitz CM; Schroeder S; Knopf P; Krahl AC; Hau J; Schleicher S; Martella M; Quintanilla-Martinez L; Kneilling M; Pichler B; Lang P; Atar D; Schilbach K; Handgretinger R; Schlegel P
    Oncoimmunology; 2020; 9(1):1683345. PubMed ID: 32002293
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.